FDA alerts patients and health care professionals to Teva's recall of valsartan products due to NDEA

Teva Pharmaceuticals has launched a voluntary recall of valsartan-containing products made using active pharmaceutical ingredient from Mylan Pharmaceuticals, which recently issued a voluntary recall of valsartan-containing products as well. Teva's recall includes all lots of amlodipine and valsartan combination tablets and amlodipine, valsartan, and hydrochlorothiazide (HCTZ) combination tablets due to the presence of N-Nitrosodiethylamine (NDEA). The company has recalled other products containing valsartan in recent months after detecting N-Nitrosodimethylamine (NDMA). With the new recall, the company has recalled all of its unexpired valsartan-containing products from the U.S. market. Additional information about the recall is available here.

Read More